Original Scientific Articles
Download PDF (49.67 MB)
Journal of Structural Heart Disease, September 2015, Volume 1, Issue 3:137-151
DOI: 10.12945/j.jshd.2015.008.14
Transcatheter Therapies for Tricuspid Valve Failure
Zakaria Jalal, MD1, Rachid Zegdi, MD, PhD2-4, Alexander Lauten, MD5, Patel Mehul, MD1, Younes Boudjemline, MD, PhD1,4,6
1 Centre de Référence Malformations Cardiaques Congénitales Complexes – M3C, Hôpital Necker-Enfants Malades, Hôpital Européen Georges Pompidou, Assistance Publique des Hôpitaux de Paris, Unité médico-chirurgicale, Paris, France
2 Inserm U970, Faculté de Necker, Paris, France;
3 Service de Chirurgie Cardiovasculaire, Hôpital Européen Georges Pompidou, AP-HP, Paris, France;
4 Université Paris Descartes, Sorbonne Paris Cité, Paris, France;
5 Klinik für Innere Medizin 1, Kardiologie, Erlanger Allee 101, 07743 Jena, Germany;
6 EA 7328 FETUS, Faculté de Necker, Paris, France
Rachid Zegdi and Alexander Lauten have contributed equally to the writing of this paper.
Abstract
Tricuspid valve failure with low output state is a growing problem in the management of structural heart disease and stage D heart failure. Severe tricuspid valve disease either due to congenital or acquired etiology constitutes high risk for palliative or definitive surgical correction. Limited progress is noted so far on the evolution of durable surgical techniques on tricuspid valve disease and spiraling down refractory right heart failure continues to be the Achilles heel in the management. Over the last decade, transcatheter therapies for the management of aortic and pulmonary valves have expanded the therapeutic options for patients deemed at high risk for conventional surgery. The interventional therapies to manage tricuspid valve failure have mostly been a surrogate use of established therapies for other valves. The numerous interventional strategies used on failing tricuspid valve include percutaneous tricuspid valvuloplasty, percutaneous valve in valve, valve-in-ring implantation, and orthotopic/heterotopic valve implantation using commercially available “off-label” device or dedicated custom-made devices. This review focuses on the different percutaneous approaches and devices that have evolved for the management of tricuspid valve failure with varying anatomical substrates such as native tricuspid valves, annuloplasty rings or bioprosthesis.
Cite this article as: Jalal Z, Zegdi R, Lauten A, Mehul P, Boudjemline Y. Transcatheter Therapies for Tricuspid Valve Failure. Structural Heart Disease 2015;1(3):137-151. DOI: 10.12945/j.jshd.2015.008.14
All comments will be screened and reviewed before posting. Statements, opinions, and results of studies published in Journal of Structural Heart Disease are those of the authors and do not reflect the policy or position of The Journal and Science International and the Editorial Board and provides no warranty as to their accuracy or reliability. Material is copyrighted and owned by Science International and cannot be used without expressed permission.
Original Scientific Articles
Journal of Structural Heart Disease, September 2015, Volume 1, Issue 3:137-151
DOI: 10.12945/j.jshd.2015.008.14
Transcatheter Therapies for Tricuspid Valve Failure
Zakaria Jalal, MD1, Rachid Zegdi, MD, PhD2-4, Alexander Lauten, MD5, Patel Mehul, MD1, Younes Boudjemline, MD, PhD1,4,6
1 Centre de Référence Malformations Cardiaques Congénitales Complexes – M3C, Hôpital Necker-Enfants Malades, Hôpital Européen Georges Pompidou, Assistance Publique des Hôpitaux de Paris, Unité médico-chirurgicale, Paris, France
2 Inserm U970, Faculté de Necker, Paris, France;
3 Service de Chirurgie Cardiovasculaire, Hôpital Européen Georges Pompidou, AP-HP, Paris, France;
4 Université Paris Descartes, Sorbonne Paris Cité, Paris, France;
5 Klinik für Innere Medizin 1, Kardiologie, Erlanger Allee 101, 07743 Jena, Germany;
6 EA 7328 FETUS, Faculté de Necker, Paris, France
Rachid Zegdi and Alexander Lauten have contributed equally to the writing of this paper.
Abstract
Tricuspid valve failure with low output state is a growing problem in the management of structural heart disease and stage D heart failure. Severe tricuspid valve disease either due to congenital or acquired etiology constitutes high risk for palliative or definitive surgical correction. Limited progress is noted so far on the evolution of durable surgical techniques on tricuspid valve disease and spiraling down refractory right heart failure continues to be the Achilles heel in the management. Over the last decade, transcatheter therapies for the management of aortic and pulmonary valves have expanded the therapeutic options for patients deemed at high risk for conventional surgery. The interventional therapies to manage tricuspid valve failure have mostly been a surrogate use of established therapies for other valves. The numerous interventional strategies used on failing tricuspid valve include percutaneous tricuspid valvuloplasty, percutaneous valve in valve, valve-in-ring implantation, and orthotopic/heterotopic valve implantation using commercially available “off-label” device or dedicated custom-made devices. This review focuses on the different percutaneous approaches and devices that have evolved for the management of tricuspid valve failure with varying anatomical substrates such as native tricuspid valves, annuloplasty rings or bioprosthesis.
PDF
Mobile-ready Flipbook
Cite this article as: Jalal Z, Zegdi R, Lauten A, Mehul P, Boudjemline Y. Transcatheter Therapies for Tricuspid Valve Failure. Structural Heart Disease 2015;1(3):137-151. DOI: 10.12945/j.jshd.2015.008.14
You must be registered and logged in to leave comments.
There have been no comments posted yet
Ask a question (publicly)
Board